The kickstarter competition was transformative for Sevenless. We were able to effectively put 10 full time FTEs on our lead optimization program, which delivered novel chemistry ahead of schedule. The progress was outstanding and the o2h team a pleasure to work with. Kickstarter did for us exactly as it’s name suggests. We are now looking to move a drug candidate forward through IND enabling studies and towards Phase I clinical trials.

Running a chemistry program is always a challenging sell to investors. The o2h kickstarter award did several things. It defrayed the cost of the program. It gave us access to a large team of skilled synthetic chemists. It allowed us to partner with experienced medicinal chemists. Finally o2hs review of our proposed program helped validate it and unlock investor funding.

The size and experience of the team allowed rapid progress, generating compounds suitable for further evaluation in our primary indications and allowed us to (successfully!) explore radically new applications of our technology.

The o2h Kickstarter competition promises to be an excellent scheme allowing early-stage companies like ours to get access to synthetic chemistry.

The Kickstarter provides vital access to chemists with the skills and knowledge to deliver on the promise of our technology.

I am thrilled that Five Alarm Bio has been awarded the Kickstarter program. We will benefit from the extensive knowledge and enthusiasm of the o2h leadership and laboratory scientists.

The Kickstarter will enable us to thoroughly explore our nascent SAR and advance our lead program more rapidly.

o2h’s Kickstarter Award has substantially accelerated our lead-series expansion plans, thanks to a professional team that has been over-delivering on some rather challenging and exciting chemistry.

We're delighted to receive o2h's Kickstarter award this year. Our primary mission is developing therapeutics to safely target processes shared by many neurodegenerative diseases as well as chronic cognitive, fatigue, and pain disorders. o2h's support of this mission is truly inspiring, and the expertise of their chemistry and biology teams serves as a vital catalyst for our first two discovery projects.

We have been fortunate enough to work with the outstanding o2h Kickstarter team, which has enabled us to move rapidly through our compound screening programme in an exceptionally cost-effective fashion. The o2h team bring great depth of expertise and experience of the pharmaceutical sector, with a strong understanding of our specific needs. The whole o2h team has worked efficiently and diligently, with high quality end results that are enabling us to reach for our long-terms goals to bring new therapeutics to cancer patients.

At Cellestial, our goal is to maximise patient benefit that our treatments can offer. Small molecule therapeutics remain the most scalable form of treatment modality, meaning that more people around the world can benefit from them. We are proud to partner with o2h to expand our pipeline of astrocyte-protective small molecule drugs. The expertise provided both on the conceptual planning stage as well as the synthesis efficiency is world-class.

We’re honored to receive o2h’s Kickstarter Award, a meaningful validation of our novel program addressing debilitating symptoms of Parkinson’s Disease. Psy's collaboration with o2h's superb chemistry team will further accelerate this high-impact program’s path to the clinic and advance our broader mission to deliver transformative treatments to patients in need.